Search PubMed⌕ Search

Biomedical subjects

L Andersson

Publications and source records attributed to L Andersson.

At least 469 records · Page 26Linked to original sources
PubMed1977

Estramustine phosphate therapy in carcinoma of the prostate.

Estramustine phosphate, a nor nitrogen mustard derivative of estradiol 17-beta-phosphate, was introduced in the treatment of prostatic carcinoma in 1966. Until March 1975, 466 patients have been reported on this treatment in open clinical trials: 82% of the patients were in stage IV. In 402 patients, nonresponsive to previous estrogen therapy, signigicant improvement occurred in 55%. In 64 previously untreated patients there was a favourable response in 83%. Side-effects were mainly bone marrow suppression. liver disturbance, thrombophlebitis following intravenous injection, and gastrointestinal troubles, mainly following oral administration. A prospective, randomized study comparing oral estramustine phosphate and conventional estrogen therapy in carcinoma of the prostate is in progress.

Administration, Oral↗
PubMed1977

Fibrinolytic activity of in vitro cultivated human bladder cell lines.

Three human bladder carcinoma cell lines, T 24, RT 4, and MANO, a human bladder nonmalignant epithelial cell line, HCV-29, and a human lung fibroblast line, 460 H1, were investigated for their ability to induce fibrinolytic, urokinase and plasmin inhibitory activities in cell culture, using serum-free medium, for up to 36 h. Generally, the non-malignant cell line and the fibroblast line had a greater ability to produce urokinase inhibitor than did the malignant cell lines. The amount produced varied greatly between cells and over the study period. A low concentration of plasminogen activator, immunologically identical with urokinase, and its accumulation in culture supernate were found with RT 4 after 12 h and 24 h cultivations, whereas no plasminogen activator was detected in all other cell lines for periods up to 36 h. No plasmin, non-specific protease or plasmin inhibitory activities were detected in any of the supernates from the cell lines.

Cell Line↗
PubMed1977

Induction of specific unresponsiveness to transplantation antigens.

Transplantation of tissue between non-identical human beings does normally require heavy, non-specific immunosuppressive treatment to be successful. Complications of severe nature are frequently induced by such therapy. Here, procedures allowing a selective immunosuppression of the recipient with regard to the donor's alloantigens would be of paramount importance as to reduce the need for non-specific immunosuppressive agents. Classical pathways to achieve specific reduction of reactivity against transplantation antigens include "transplantation tolerance" and "enhancement". Although occasional successful when using adult, immunocompetent individuals in experimental animal systems these approaches have so far failed to leave impressive impacts with regard to the human transplantation immunologists. In the present article an entirely new concept will be introduced, namely that of auto-anti-idiotypic immunity leading to specific lack of reactivity towards transplantation antigens. The principle and the underlying results supporting the concept wil be presented and the practical implications will be discussed.

Animals↗
PubMed1974

Serum alpha-fetoprotein: diagnostic significance in liver disease.

Raised serum alpha-fetoprotein levels measured by radioimmunoassay were found in 19 out of 24 (79%) patients with primary liver cancer and in 32 out of 311 (10%) patients with other liver diseases. The rise was transient in cases of hepatitis and a transient rise was also seen after alcohol intake ceased in two patients with cirrhosis. alpha-Fetoprotein levels exceeding 500 ng/ml were 30-50 times more common in primary liver cancer than in other liver diseases. A rise in level seems to reflect the extent of liver regeneration in liver diseases other than primary cancer.

Biopsy↗